Exelixis, Inc. (EXEL) P/E Ratio History
UndervaluedTrading at 20.5x vs 5Y avg 29.8x · 40th percentile · Below historical baseline · Data 2011–2026
Loading P/E history...
P/E Ratio Analysis
As of July 8, 2026, Exelixis, Inc. (EXEL) trades at a price-to-earnings ratio of 20.5x, with a stock price of $57.08 and trailing twelve-month earnings per share of $3.12.
The current P/E is 31% below its 5-year average of 29.8x. Over the past five years, EXEL's P/E has ranged from a low of 14.5x to a high of 78.0x, placing the current valuation at the 40th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.4x, EXEL is roughly in line with its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 198.8x.
The PEG ratio of 0.40 (P/E divided by 58% EPS growth) suggests the stock may be undervalued relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, EXEL trades at a notable discount to the S&P 500 median P/E of 25.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our EXEL DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
EXEL Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
EXEL P/E vs Peers
Oncology Therapeutics Developers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $24B | 18.4 | - | +4173%Best | |
| $9B | 38.6 | - | -34% | |
| $10B | 31.9 | 1.39 | -25% | |
| $4B | 11.4Lowest | - | +68% | |
| $318B | 17.7 | 0.83Best | +8% | |
| $118B | 16.8 | - | +178% | |
| $8B | 162.6 | - | +287% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
EXEL Historical P/E Data (2011–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | Apr 03 2026 | $43.88 | $3.02 | 14.5x | -59% |
| FY2025 Q4 | Jan 02 2026 | $43.58 | $2.78 | 15.7x | -56% |
| FY2025 Q3 | Oct 03 2025 | $40.09 | $2.37 | 16.9x | -53% |
| FY2025 Q2 | Jul 04 2025 | $46.15 | $2.07 | 22.3x | -38% |
| FY2025 Q1 | Apr 04 2025 | $34.57 | $2.19 | 15.8x | -56% |
| FY2024 Q4 | - | $33.30 | $1.76 | 18.9x | -47% |
| FY2024 Q3 | Sep 27 2024 | $25.96 | $1.56 | 16.6x | -54% |
| FY2024 Q2 | Jun 28 2024 | $22.47 | $1.16 | 19.3x | -46% |
| FY2024 Q1 | Mar 29 2024 | $23.73 | $0.64 | 36.9x | +3% |
| FY2023 Q4 | Dec 31 2023 | $23.99 | $0.64 | 37.3x | +4% |
| FY2023 Q3 | Sep 29 2023 | $21.85 | $0.28 | 78.0x | +118% |
| FY2023 Q2 | Jun 30 2023 | $19.11 | $0.51 | 37.7x | +5% |
| FY2023 Q1 | Mar 31 2023 | $19.41 | $0.48 | 40.7x | +14% |
| FY2022 Q4 | Dec 31 2022 | $16.04 | $0.57 | 28.3x | -21% |
| FY2022 Q3 | Sep 30 2022 | $15.68 | $0.95 | 16.5x | -54% |
| FY2022 Q2 | Jul 01 2022 | $21.57 | $0.84 | 25.7x | -28% |
| FY2022 Q1 | Apr 01 2022 | $22.89 | $0.92 | 24.9x | -31% |
| FY2021 Q4 | Dec 31 2021 | $18.28 | $0.71 | 25.6x | -29% |
| FY2021 Q3 | Oct 01 2021 | $21.54 | $0.52 | 41.8x | +17% |
| FY2021 Q2 | Jul 02 2021 | $18.26 | $0.29 | 61.9x | +73% |
| FY2021 Q1 | Apr 02 2021 | $23.12 | $0.20 | 112.8x | +215% |
| FY2020 Q4 | - | $20.07 | $0.35 | 57.3x | +60% |
| FY2020 Q3 | Oct 02 2020 | $23.40 | $0.48 | 48.8x | +36% |
| FY2020 Q2 | Jul 03 2020 | $23.48 | $0.89 | 26.4x | -26% |
| FY2020 Q1 | Apr 03 2020 | $16.52 | $0.93 | 17.8x | -50% |
| FY2019 Q4 | - | $17.62 | $1.02 | 17.3x | -52% |
| FY2019 Q3 | Sep 27 2019 | $18.00 | $1.95 | 9.2x | -74% |
| FY2019 Q2 | Jun 28 2019 | $21.37 | $2.05 | 10.4x | -71% |
| FY2019 Q1 | Mar 29 2019 | $23.80 | $2.08 | 11.4x | -68% |
| FY2018 Q4 | Dec 31 2018 | $19.67 | $2.21 | 8.9x | -75% |
| FY2018 Q3 | Sep 28 2018 | $17.72 | $1.18 | 15.0x | -58% |
| FY2018 Q2 | Jun 29 2018 | $21.52 | $1.03 | 20.9x | -42% |
| FY2018 Q1 | Mar 30 2018 | $22.15 | $0.81 | 27.3x | -24% |
| FY2017 Q4 | Dec 31 2017 | $30.40 | $0.49 | 62.0x | +73% |
| FY2017 Q3 | Sep 29 2017 | $24.23 | $0.49 | 49.4x | +38% |
| FY2017 Q2 | Jun 30 2017 | $24.63 | $0.19 | 132.4x | +270% |
| FY2012 Q2 | Jun 29 2012 | $5.53 | $0.52 | 10.6x | -70% |
| FY2012 Q1 | Mar 30 2012 | $5.18 | $0.61 | 8.5x | -76% |
| FY2011 Q4 | Dec 31 2011 | $4.74 | $0.55 | 8.6x | -76% |
| FY2011 Q3 | Sep 30 2011 | $5.46 | $0.03 | 182.0x | +408% |
Average P/E for displayed period: 35.8x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
15+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
EXEL — Frequently Asked Questions
Quick answers to the most common questions about buying EXEL stock.
What is EXEL's P/E ratio?
Exelixis, Inc. (EXEL) trailing twelve-month P/E ratio is 20.5x, based on TTM diluted EPS of $3.12. The 5-year average P/E is 29.8x and the historical range spans 14.5x to 78.0x.
Is EXEL stock overvalued or undervalued?
EXEL trades at 20.5x P/E, below its 5-year average of 29.8x. At the 40th percentile of its historical range (14.5x–78.0x), the stock is priced at a discount to its own history.
Is EXEL stock expensive?
No, EXEL is not expensive on a historical basis. The current P/E of 20.5x is below the 5-year average of 29.8x and sits at the 40th percentile of its valuation range.
What is EXEL's historical P/E range?
Over the past 5 years, EXEL's P/E ratio has ranged from 14.5x to 78.0x, with a median of 25.6x and an average of 29.8x. The current P/E of 20.5x places the stock at the 40th percentile of this range. Full historical data spans 2011–2026.
How does EXEL's P/E compare to the S&P 500?
EXEL trades at 20.5x P/E versus the S&P 500 median of 25.9x. The 21% discount to the market suggests lower growth expectations or perceived higher risk.
How does EXEL's valuation compare to Healthcare peers?
Exelixis, Inc. P/E of 20.5x compares to the Healthcare sector median of 23.4x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is EXEL's PEG ratio?
EXEL PEG ratio is 0.40, based on a P/E of 20.5x and EPS growth of 58.0%. A PEG below 1.0 indicates the valuation is supported by the earnings growth rate — typically considered attractive.
What is EXEL's earnings yield?
EXEL earnings yield is 4.87%, the inverse of its 20.5x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.